{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:46:38Z","timestamp":1792788398195,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-72986-9","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T12:42:41Z","timestamp":1726663361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world study on the efficacy and safety of different treatment regimens in treatment-na\u00efve CHB patients with high viral load"],"prefix":"10.1038","volume":"14","author":[{"given":"Xue","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongshan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"72986_CR1","unstructured":"The guideline of prevention. And treatment for chronic hepatitis B [J]. Chin. J. Clini Hepatol., (01): 3\u201315 (2006)."},{"key":"72986_CR2","unstructured":"Oncology, C. S. O. C. Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2020 Edition) [J]. (2020)."},{"key":"72986_CR3","doi-asserted-by":"publisher","unstructured":"EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection [J]. J Hepatol, 2017, 67(2): 370\u2009\u2013\u200998.DOI: (2017). https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021","DOI":"10.1016\/j.jhep.2017.03.021"},{"issue":"4","key":"72986_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance [J]. Hepatology. 67 (4), 1560\u20131599. https:\/\/doi.org\/10.1002\/hep.29800 (2018).","journal-title":"Hepatology"},{"issue":"3","key":"72986_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","volume":"119","author":"HLY Chan","year":"2024","unstructured":"Chan, H. L. Y. et al. Long-term treatment with Tenofovir Alafenamide for Chronic Hepatitis B results in high rates of viral suppression and favorable renal and bone safety [J]. Am. J. Gastroenterol.119 (3), 486\u2013496. https:\/\/doi.org\/10.14309\/ajg.0000000000002468 (2024).","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"72986_CR6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal, K. et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection [J]. J. Hepatol.68 (4), 672\u2013681. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.039 (2018).","journal-title":"J. Hepatol."},{"issue":"23","key":"72986_CR7","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1097\/CM9.0000000000001793","volume":"134","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients [J]. Chin. Med. J. (Engl). 134 (23), 2810\u20132817. https:\/\/doi.org\/10.1097\/CM9.0000000000001793 (2021).","journal-title":"Chin. Med. J. (Engl)"},{"issue":"5","key":"72986_CR8","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/gutjnl-2014-308353","volume":"65","author":"Y-S Lim","year":"2016","unstructured":"Lim, Y-S. et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial [J]. Gut. 65 (5), 852\u2013860. https:\/\/doi.org\/10.1136\/gutjnl-2014-308353 (2016).","journal-title":"Gut"},{"issue":"4","key":"72986_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","volume":"20","author":"SG Lim","year":"2023","unstructured":"Lim, S. G. et al. The scientific basis of combination therapy for chronic hepatitis B functional cure [J]. Nat. Rev. Gastroenterol. Hepatol.20 (4), 238\u2013253. https:\/\/doi.org\/10.1038\/s41575-022-00724-5 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"72986_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault, N. A. et al. AASLD guidelines for treatment of chronic hepatitis B [J]. Hepatology. 63 (1), 261\u2013283. https:\/\/doi.org\/10.1002\/hep.28156 (2016).","journal-title":"Hepatology"},{"key":"72986_CR11","doi-asserted-by":"publisher","unstructured":"Gane, E. J. et al. Telbivudine improves renal function in patients with chronic hepatitis B [J]. Gastroenterology. 146 (1). https:\/\/doi.org\/10.1053\/j.gastro.2013.09.031 (2014).","DOI":"10.1053\/j.gastro.2013.09.031"},{"issue":"12","key":"72986_CR12","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1007\/s10620-019-05717-0","volume":"64","author":"L-Y Mak","year":"2019","unstructured":"Mak, L-Y. et al. In Vitro and in vivo Renoprotective effects of Telbivudine in Chronic Hepatitis B patients receiving Nucleotide Analogue [J]. Dig. Dis. Sci.64 (12), 3630\u20133641. https:\/\/doi.org\/10.1007\/s10620-019-05717-0 (2019).","journal-title":"Dig. Dis. Sci."},{"issue":"3","key":"72986_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/jmv.25608","volume":"92","author":"Y-H Wang","year":"2020","unstructured":"Wang, Y-H. et al. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir [J]. J. Med. Virol.92 (3), 302\u2013308. https:\/\/doi.org\/10.1002\/jmv.25608 (2020).","journal-title":"J. Med. Virol."},{"issue":"3","key":"72986_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3350\/cmh.2019.0044n","volume":"26","author":"HY Woo","year":"2020","unstructured":"Woo, H. Y. et al. Entecavir\u2009+\u2009tenofovir vs. lamivudine\/telbivudine\u2009+\u2009adefovir in chronic hepatitis B patients with prior suboptimal response [J]. Clin. Mol. Hepatol.26 (3), 352\u2013363. https:\/\/doi.org\/10.3350\/cmh.2019.0044n (2020).","journal-title":"Clin. Mol. Hepatol."},{"issue":"7","key":"72986_CR15","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/MEG.0000000000001345","volume":"31","author":"Z-X Wu","year":"2019","unstructured":"Wu, Z-X. et al. Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: an open-label, randomized, controlled study [J]. Eur. J. Gastroenterol. Hepatol.31 (7), 832\u2013835. https:\/\/doi.org\/10.1097\/MEG.0000000000001345 (2019).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"6","key":"72986_CR16","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/gutjnl-2014-308435","volume":"65","author":"Y-S Lim","year":"2016","unstructured":"Lim, Y-S. et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial [J]. Gut. 65 (6), 1042\u20131051. https:\/\/doi.org\/10.1136\/gutjnl-2014-308435 (2016).","journal-title":"Gut"},{"issue":"01","key":"72986_CR17","first-page":"73","volume":"20","author":"F Shuai","year":"2020","unstructured":"Shuai, F. & Xiao-Ning, L. The research development of formulas for calculating glomerular filtration rate:from Cockcroft-Gault formula to full age spectrum (FAS) formula [J]. J. Clin. Nephrol.20 (01), 73\u201377 (2020).","journal-title":"J. Clin. Nephrol."},{"issue":"28","key":"72986_CR18","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin, P. C. & Stuart, E. A. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies [J]. Stat. Med.34 (28), 3661\u20133679. https:\/\/doi.org\/10.1002\/sim.6607 (2015).","journal-title":"Stat. Med."},{"issue":"1","key":"72986_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","volume":"7","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z. et al. Balance diagnostics after propensity score matching [J]. Ann. Transl Med.7 (1), 16. https:\/\/doi.org\/10.21037\/atm.2018.12.10 (2019).","journal-title":"Ann. Transl Med."},{"key":"72986_CR20","unstructured":"Jacob, C. Statistical Power Analysis for the Behavioral Sciences [J] (Lawrence Erlbaum Associates, 1988)."},{"issue":"2","key":"72986_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3760\/cma.j.cn501113-20220209-00060","volume":"30","author":"Expert opinion on expanding anti-HBV treatment for chronic hepatitis B [J]","year":"2022","unstructured":"Expert opinion on expanding anti-HBV treatment for chronic hepatitis B [J]. Zhonghua Gan Zang Bing Za Zhi, 30(2): 131\u2013136. DOI:https:\/\/doi.org\/10.3760\/cma.j.cn501113-20220209-00060 (2022).","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"3","key":"72986_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HLY Chan","year":"2016","unstructured":"Chan, H. L. Y. et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial [J]. Lancet Gastroenterol. Hepatol.1 (3), 185\u2013195. https:\/\/doi.org\/10.1016\/S2468-1253(16)30024-3 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"72986_CR23","doi-asserted-by":"publisher","first-page":"100738","DOI":"10.1016\/j.lanwpc.2023.100738","volume":"35","author":"S Zhang","year":"2023","unstructured":"Zhang, S. et al. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation [J]. Lancet Reg. Health West. Pac.35, 100738. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100738 (2023).","journal-title":"Lancet Reg. Health West. Pac."},{"key":"72986_CR24","doi-asserted-by":"publisher","unstructured":"Chien, R. N. & Liaw, Y. F. Current Trend in Antiviral Therapy for Chronic Hepatitis B [J]. Viruses. 14 (2). https:\/\/doi.org\/10.3390\/v14020434 (2022).","DOI":"10.3390\/v14020434"},{"issue":"6","key":"72986_CR25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.14218\/JCTH.2023.00320","volume":"11","author":"H You","year":"2023","unstructured":"You, H. et al. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022) [J]. J. Clin. Transl Hepatol.11 (6), 1425\u20131442. https:\/\/doi.org\/10.14218\/JCTH.2023.00320 (2023).","journal-title":"J. Clin. Transl Hepatol."},{"issue":"6","key":"72986_CR26","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3969\/j.issn.1001-5256.2021.06.007","volume":"37","author":"L Fengming","year":"2021","unstructured":"Fengming, L., Bo, F. & Suzhen, Z. Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues [J]. J. Clin. Hepatol.37 (6), 1268\u20131274. https:\/\/doi.org\/10.3969\/j.issn.1001-5256.2021.06.007 (2021).","journal-title":"J. Clin. Hepatol."},{"issue":"9","key":"72986_CR27","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/jmv.24201","volume":"87","author":"HJ Cho","year":"2015","unstructured":"Cho, H. J. et al. Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance [J]. J. Med. Virol.87 (9), 1532\u20131538. https:\/\/doi.org\/10.1002\/jmv.24201 (2015).","journal-title":"J. Med. Virol."},{"key":"72986_CR28","doi-asserted-by":"publisher","unstructured":"Lok, A. S. et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na\u00efve patients with chronic hepatitis B [J]. Gastroenterology. 143 (3). https:\/\/doi.org\/10.1053\/j.gastro.2012.05.037 (2012).","DOI":"10.1053\/j.gastro.2012.05.037"},{"issue":"2","key":"72986_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/jvh.12623","volume":"24","author":"S Lee","year":"2017","unstructured":"Lee, S. et al. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance [J]. J. Viral Hepat.24 (2), 141\u2013147. https:\/\/doi.org\/10.1111\/jvh.12623 (2017).","journal-title":"J. Viral Hepat."},{"issue":"2","key":"72986_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40121-014-0039-5","volume":"3","author":"NWY Leung","year":"2014","unstructured":"Leung, N. W. Y. et al. Early viral kinetics with Telbivudine, tenofovir or combination of both in Immunotolerant patients with Hepatitis B E Antigen-positive chronic Hepatitis B [J]. Infect. Dis. Ther.3 (2), 191\u2013202. https:\/\/doi.org\/10.1007\/s40121-014-0039-5 (2014).","journal-title":"Infect. Dis. Ther."},{"issue":"5 Suppl","key":"72986_CR31","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1002\/hep.22921","volume":"49","author":"NA Terrault","year":"2009","unstructured":"Terrault, N. A. Benefits and risks of combination therapy for hepatitis B [J]. Hepatology. 49 (5 Suppl), S122\u2013S8. https:\/\/doi.org\/10.1002\/hep.22921 (2009).","journal-title":"Hepatology"},{"issue":"1","key":"72986_CR32","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1186\/s12879-021-06554-1","volume":"21","author":"J Shang","year":"2021","unstructured":"Shang, J. et al. Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients [J]. BMC Infect. Dis.21 (1), 912. https:\/\/doi.org\/10.1186\/s12879-021-06554-1 (2021).","journal-title":"BMC Infect. Dis."},{"issue":"5","key":"72986_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4103\/sjg.SJG_537_18","volume":"25","author":"A Jindal","year":"2019","unstructured":"Jindal, A. et al. A randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B [J]. Saudi J. Gastroenterol.25 (5), 319\u2013326. https:\/\/doi.org\/10.4103\/sjg.SJG_537_18 (2019).","journal-title":"Saudi J. Gastroenterol."},{"issue":"3","key":"72986_CR34","doi-asserted-by":"publisher","first-page":"e0149761","DOI":"10.1371\/journal.pone.0149761","volume":"11","author":"MC Tsai","year":"2016","unstructured":"Tsai, M. C. et al. Does Nucleos(t)ide Analogues Treatment affect renal function in Chronic Hepatitis B patients who have already decreased eGFR? A longitudinal study [J]. PLoS One. 11 (3), e0149761. https:\/\/doi.org\/10.1371\/journal.pone.0149761 (2016).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72986-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72986-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72986-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T15:03:36Z","timestamp":1726844616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72986-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["72986"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-72986-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was approved by the ethics Committee of Shenzhen Nanshan People\u2019s hospital (number: KY-2024-003-01), and patients are exempted from informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"21656"}}